In the open‐label, phase III CheckMate 816 study (NCT02998528), neoadjuvant nivolumab
plus chemotherapy demonstrated statistically significant improvements in event‐free survival …

Background: Accurate molecular testing in non-small-cell lung cancer (NSCLC) is of
paramount importance for treatment, prediction, and prognostication. Objectives: We aimed …

Previous studies have investigated the association between reproductive factors and lung
cancer risk; however, findings have been inconsistent. In order to assess this association …

Background Recent reports suggested combining ramucirumab with epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non …

Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have
limited or no response in some certain patients of non-small-cell lung cancer (NSCLC) …

Purpose: To investigate the effect of DC-CIK immune cells labeled with anti-CD3-EGFR
bispecific antibody (BSAB) on the proliferation of lung cancer (LC) cells in order to generate …

The high expression of epidermal growth factor receptor (EGFR) in carcinomas from multiple
tissue sites led to preclinical studies and early trials assessing the efficacy of EGFR …

Lung cancer is becoming the most common cancer globally. In China, Lung cancer has
become prevalent among preceding compared to present smokers. There are many …

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with an
extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase …

Neuroendocrine lung tumors are rare neoplasms, with an increasing incidence in the last
thirty years. Metastatic disease is rarely curable. We present the case of a 65-year-old male …